157 related articles for article (PubMed ID: 20002883)
1. Clinically relevant drug interactions of current antifungal agents.
Gubbins PO; Heldenbrand S
Mycoses; 2010 Mar; 53(2):95-113. PubMed ID: 20002883
[TBL] [Abstract][Full Text] [Related]
2. Management of drug and food interactions with azole antifungal agents in transplant recipients.
Dodds-Ashley E
Pharmacotherapy; 2010 Aug; 30(8):842-54. PubMed ID: 20653361
[TBL] [Abstract][Full Text] [Related]
3. Mould-active azoles: pharmacokinetics, drug interactions in neutropenic patients.
Gubbins PO
Curr Opin Infect Dis; 2007 Dec; 20(6):579-86. PubMed ID: 17975407
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.
Brüggemann RJ; Alffenaar JW; Blijlevens NM; Billaud EM; Kosterink JG; Verweij PE; Burger DM
Clin Infect Dis; 2009 May; 48(10):1441-58. PubMed ID: 19361301
[TBL] [Abstract][Full Text] [Related]
5. Antifungal serum concentration monitoring: an update.
Goodwin ML; Drew RH
J Antimicrob Chemother; 2008 Jan; 61(1):17-25. PubMed ID: 17999982
[TBL] [Abstract][Full Text] [Related]
6. The current role of amphotericin B lipid complex in managing systemic fungal infections.
Chu P; Sadullah S
Curr Med Res Opin; 2009 Dec; 25(12):3011-20. PubMed ID: 19849324
[TBL] [Abstract][Full Text] [Related]
7. [Update on the pharmacological interactions of systemic antifungal agents].
Viudes A; Pemán J; Cantón E; Ubeda P; Gobernado M
Rev Esp Quimioter; 1999 Jun; 12(2):107-15. PubMed ID: 10562670
[TBL] [Abstract][Full Text] [Related]
8. Management of systemic fungal infections: alternatives to itraconazole.
Herbrecht R; Nivoix Y; Fohrer C; Natarajan-Amé S; Letscher-Bru V
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i39-i48. PubMed ID: 16120633
[TBL] [Abstract][Full Text] [Related]
9. Interactions between antifungal and antiretroviral agents.
Hughes CA; Foisy M; Tseng A
Expert Opin Drug Saf; 2010 Sep; 9(5):723-42. PubMed ID: 20345324
[TBL] [Abstract][Full Text] [Related]
10. How to select an antifungal agent in critically ill patients.
Dimopoulos G; Antonopoulou A; Armaganidis A; Vincent JL
J Crit Care; 2013 Oct; 28(5):717-27. PubMed ID: 24018296
[TBL] [Abstract][Full Text] [Related]
11. Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders.
Worth LJ; Blyth CC; Booth DL; Kong DC; Marriott D; Cassumbhoy M; Ray J; Slavin MA; Wilkes JR
Intern Med J; 2008 Jun; 38(6b):521-37. PubMed ID: 18588523
[TBL] [Abstract][Full Text] [Related]
12. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.
Slavin MA; Szer J; Grigg AP; Roberts AW; Seymour JF; Sasadeusz J; Thursky K; Chen SC; Morrissey CO; Heath CH; Sorrell T
Intern Med J; 2004 Apr; 34(4):192-200. PubMed ID: 15086700
[TBL] [Abstract][Full Text] [Related]
13. [Future directions of antimycotic therapy].
Meunier F
Mycoses; 1994; 37 Suppl 2():77-82. PubMed ID: 7541893
[TBL] [Abstract][Full Text] [Related]
14. Invasive fungal infection--laboratory diagnosis and antifungal treatment.
Shao PL; Huang LM; Hsueh PR
J Microbiol Immunol Infect; 2006 Jun; 39(3):178-88. PubMed ID: 16783447
[TBL] [Abstract][Full Text] [Related]
15. Fluconazole: a new antifungal agent.
Kowalsky SF; Dixon DM
Clin Pharm; 1991 Mar; 10(3):179-94. PubMed ID: 2040125
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations.
Smith J; Andes D
Ther Drug Monit; 2008 Apr; 30(2):167-72. PubMed ID: 18367976
[TBL] [Abstract][Full Text] [Related]
17. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.
Bellmann R; Cleary JD; Sterba J
Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-8. PubMed ID: 19537331
[TBL] [Abstract][Full Text] [Related]
18. Changing strategies for the management of invasive fungal infections.
Rapp RP
Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
[TBL] [Abstract][Full Text] [Related]
19. Newer antifungal agents for invasive fungal infections in patients with haematological malignancy.
Rogers TR; Frost S
Br J Haematol; 2009 Mar; 144(5):629-41. PubMed ID: 19120371
[TBL] [Abstract][Full Text] [Related]
20. Immunocompromised hosts: immunopharmacology of modern antifungals.
Ben-Ami R; Lewis RE; Kontoyiannis DP
Clin Infect Dis; 2008 Jul; 47(2):226-35. PubMed ID: 18540822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
